 CAMBRIDGE, Mass., March 8, 2022 PRNewswire -- Omega Therapeutics, Inc. Nasdaq: OMGA Omega, a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic ProgramingTM platform, today announced that it will present preclinical data for OTX-2002, the Companys lead drug candidate for the treatment of hepatocellular carcinoma HCC, at the upcoming American Association for Cancer Research AACR Annual Meeting 2022, taking place in New Orleans, Louisiana, April 8-13, 2022. 